These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 20008760)

  • 1. Effectiveness and cost-effectiveness of expanded antiviral prophylaxis and adjuvanted vaccination strategies for an influenza A (H5N1) pandemic.
    Khazeni N; Hutton DW; Garber AM; Owens DK
    Ann Intern Med; 2009 Dec; 151(12):840-53. PubMed ID: 20008760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and cost-effectiveness of vaccination against pandemic influenza (H1N1) 2009.
    Khazeni N; Hutton DW; Garber AM; Hupert N; Owens DK
    Ann Intern Med; 2009 Dec; 151(12):829-39. PubMed ID: 20008759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Summaries for patients. Assessing the best way to prevent spread of influenza.
    Ann Intern Med; 2009 Dec; 151(12):I31. PubMed ID: 20008744
    [No Abstract]   [Full Text] [Related]  

  • 4. Health and economic benefits of early vaccination and nonpharmaceutical interventions for a human influenza A (H7N9) pandemic: a modeling study.
    Khazeni N; Hutton DW; Collins CI; Garber AM; Owens DK
    Ann Intern Med; 2014 May; 160(10):684-94. PubMed ID: 24842415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of vaccination against pandemic influenza in European countries: mathematical modelling analysis.
    Lugnér AK; van Boven M; de Vries R; Postma MJ; Wallinga J
    BMJ; 2012 Jul; 345():e4445. PubMed ID: 22791791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of Strategies for Offering Influenza Vaccine in the Pediatric Emergency Department.
    Hart RJ; Stevenson MD; Smith MJ; LaJoie AS; Cross K
    JAMA Pediatr; 2018 Jan; 172(1):e173879. PubMed ID: 29114729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of 2009 pandemic influenza A(H1N1) vaccination in the United States.
    Prosser LA; Lavelle TA; Fiore AE; Bridges CB; Reed C; Jain S; Dunham KM; Meltzer MI
    PLoS One; 2011; 6(7):e22308. PubMed ID: 21829456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of influenza A(H5N1) vaccine stored up to twelve years in the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS).
    Oshansky CM; Zhou J; Gao Y; Schweinle JE; Biscardi K; DeBeauchamp J; Pavetto C; Wollish A; ; Webby RJ; Cioce V; Donis RO; Bright RA
    Vaccine; 2019 Jan; 37(3):435-443. PubMed ID: 30553570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis.
    Rothberg MB; Rose DN
    Am J Med; 2005 Jan; 118(1):68-77. PubMed ID: 15639212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The modern crystal ball: influenza forecasting with mathematical models.
    Kansagra SM; Farley TA
    Ann Intern Med; 2009 Dec; 151(12):886-7. PubMed ID: 20008763
    [No Abstract]   [Full Text] [Related]  

  • 11. Antiviral agents for influenza: a comparison of cost-effectiveness data.
    Lynd LD; Goeree R; O'Brien BJ
    Pharmacoeconomics; 2005; 23(11):1083-106. PubMed ID: 16277546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness and Public Health Effect of Influenza Vaccine Strategies for U.S. Elderly Adults.
    Raviotta JM; Smith KJ; DePasse J; Brown ST; Shim E; Nowalk MP; Zimmerman RK
    J Am Geriatr Soc; 2016 Oct; 64(10):2126-2131. PubMed ID: 27709600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of Pediatric Influenza Vaccination in The Netherlands.
    de Boer PT; Nagy L; Dolk FCK; Wilschut JC; Pitman R; Postma MJ
    Value Health; 2021 Jan; 24(1):19-31. PubMed ID: 33431149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of pharmaceutical-based pandemic influenza mitigation strategies.
    Newall AT; Wood JG; Oudin N; MacIntyre CR
    Emerg Infect Dis; 2010 Feb; 16(2):224-30. PubMed ID: 20113551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B.
    Hutton DW; Tan D; So SK; Brandeau ML
    Ann Intern Med; 2007 Oct; 147(7):460-9. PubMed ID: 17909207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic analysis of pandemic influenza vaccination strategies in Singapore.
    Lee VJ; Tok MY; Chow VT; Phua KH; Ooi EE; Tambyah PA; Chen MI
    PLoS One; 2009 Sep; 4(9):e7108. PubMed ID: 19771173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing optimal use of the standard dose adjuvanted trivalent seasonal influenza vaccine in the elderly.
    Thorrington D; van Leeuwen E; Ramsay M; Pebody R; Baguelin M
    Vaccine; 2019 Apr; 37(15):2051-2056. PubMed ID: 30871927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implementing an influenza vaccination programme for adults aged ≥65 years in Poland: a cost-effectiveness analysis.
    Brydak L; Roiz J; Faivre P; Reygrobellet C
    Clin Drug Investig; 2012 Feb; 32(2):73-85. PubMed ID: 22201294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of quadrivalent versus trivalent influenza vaccine in Taiwan: A lifetime multi-cohort model.
    Yang MC; Tan EC; Su JJ
    Hum Vaccin Immunother; 2017 Jan; 13(1):81-89. PubMed ID: 27624648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B.
    Turner D; Wailoo A; Nicholson K; Cooper N; Sutton A; Abrams K
    Health Technol Assess; 2003; 7(35):iii-iv, xi-xiii, 1-170. PubMed ID: 14609480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.